Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies

Current Opinion in Oncology

Volumn 13, Issue 5, 2001, Pages 360-367

  Faller, Douglas V ^a   Mentzer, Steven J ^b,c   Perrine, Susan P ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ARGININE BUTYRATE; GANCICLOVIR; NUCLEOSIDE ANALOG; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; CLINICAL TRIAL; DISEASE COURSE; EPSTEIN BARR VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LATENT VIRUS INFECTION; LYMPHOPROLIFERATIVE DISEASE; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; ARGININE; BUTYRATES; CLINICAL TRIALS; COMBINED MODALITY THERAPY; ENZYME INDUCTION; EPSTEIN-BARR VIRUS INFECTIONS; GANCICLOVIR; GENE EXPRESSION REGULATION, NEOPLASTIC; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA, NON-HODGKIN; PROGNOSIS; THYMIDINE KINASE;

EID: 0034858563     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200109000-00008     Document Type: Review

References (101)

1. Epstein-Barr virus
2. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2
3. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relation to the C3d complement receptor (CR2)
4. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates absorption, capping, and endocytosis
5. Epstein-Barr virus: Biology, pathogenesis, and medical aspects
6. Epstein-Barr virus and its replication
7. Recent developments in molecular genetics of Epstein-Barr virus
8. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells
9. Epstein-Barr virus-associated disease in humans
10. Chronic, active Epstein-Barr virus infection
11. Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis
12. Epstein-Barr virus and human malignancies
13. T-cell lymphomas containing Epstein-Barr virus DNA in patients with chronic Epstein-Barr virus infections
14. Detection of Epstein-Barr virus in Reed-Sternberg cells of Hodgkin's disease
15. Epstein-Barr virus: The first human tumor virus and its role in cancer
16. Epstein-Barr virus and lymphomas
17. Replication of Epstein-Barr virus within the epithelial cells of oral 'hairy' leukoplakia, an AIDS-associated lesion
18. Epstein-Barr virus-induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation
19. Epstein-Barr virus-induced diseases in boys with the X-linked lymphoproliferative syndrome (XLP): Updates on studies of the registry
20. X-linked lymphoproliferative disease: Genetics and biochemistry
21. X-linked lymphoproliferative disease: A progressive immunodeficiency
22. X-linked lymphoproliferative disease is caused by deficiency of a novel SH2 domain-containing signal transduction adaptor protein
23. Overview of the epidemiology of malignancy in immune deficiency
24. Current perspectives on the molecular pathogenesis of virus-induced cancers in human immunodeficiency virus infection and acquired immunodeficiency syndrome
25. AIDS-associated malignancies: Research perspectives
26. Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy
27. Combination antiretroviral therapy and incidence of AIDS-related malignancies
28. Acquired immunodeficiency syndrome-related lymphomas: Future directions
29. The molecular basis of acquired immunodeficiency syndrome-related lymphomagenesis
30. Lymphomas and reactive lymphoid lesions in HIV infection
31. Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas
32. Epstein-Barr virus, the CNS, and AIDS-related lymphomas: As close as flame to smoke
33. HIV-associated Hodgkin's disease
34. Epstein-Barr virus in Hodgkin's disease: Correlation of risk factors and disease characteristics with molecular evidence of viral infection
35. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: A distinct entity?
36. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency
37. Posttransplant lymphoproliferative disease following renal transplantation: A multicenter retrospective study of 41 cases observed between 1992 and 1996
38. Transplantation-related lymphoproliferative disorder: A model for human immunodeficiency virus-related lymphomas
39. Genotypic and phenotypic alterations in Epstein-Barr virus-associated lymphoma
40. Early identification of Epstein-Barr virus-associated post- transplantation lymphoproliferative disease
41. The pathology of post-transplant lymphoproliferative disorders occurring in the setting of cyclosporin Aprednisone immunosuppression
42. Aggressive treatment for postcardiac transplant lymphoproliferation
43. Clinical characteristics of posttransplant lymphoproliferative disorders
44. The role of EBV in post-transplant malignancies: A review
45. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children
46. Factors affecting survival after orthotopic liver transplantation in infants
47. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for postransplantation lymphoproliferative disorder in adult heart, lung and other solid organ transplantations
48. Epstein-Barr virus transmission via the donor organs in solid organ transplantation: Polymerase chain reaction and restriction fragment length polymorphism analysis of IR2, IR3, and IR4
49. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: The role of primary infection
50. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: Ten years of cyclosporine-based immunosuppression
51. Immunoblastic lymphoma of donor origin after lung transplantation
52. Immune reconstitution in ADIS
53. Lymphoma in cardiac transplant recipients associated with cyclosporin A, prednisone and anti-thymocyte globulin (ATG)
54. BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome
55. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorder after allogeneic bone marrow transplantation
56. The role of adoptive immunotherapy in the prevention and treatment of lymphoproliferative disease following transplantation
57. Immunotherapy for Epstein-Barr virus-associated cancers
58. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
59. Epstein-Barr virus and the immune system: Hide and seek
60. Identification of an Epstein-Barr virus-coded thymidine kinase
61. Epstein-Barr virus induces a unique pyrimidine deoxynucleoside kinase activity in superinfected and virus-producer B cell lines
62. Prolonged inhibitory effect of 9-(1,3-Dihydroxy-2-propoxymethyl) guanine against replication of Epstein-Barr virus
63. Characterization of the Epstein-Barr virus-encoded thymidine kinase expressed in heterologous eucaryotic and procaryotic systems
64. The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared with the herpes simplex virus type 1 thymidine kinase
65. In vive gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
66. Gene transfer of herpes simplex virus type I thymidine kinase gene as a drug sensitivity gene into human lung cancer cell lines using retroviral vectors
67. Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo
68. Resolution of oral hairy leukoplakia during therapy with 9-(1,3-dihydroxy-2-propoxymethyl) guanine (DHPG)
69. Regression of oral hairy leukoplakia after orally administered acyclovir therapy
70. The clinical diversity and role of chemotherapy in lymphoproliferative disorder in liver transplant recipients
71. Posttransplantation cutaneous B-cell lymphoma with monoclonal Epstein-Barr virus infection, responding to acyclovir and reduction in immunosuppression
72. Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir: Two cases after solid organ transplantation
73. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: Acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation
74. Effects of n-butyrate and phorbol ester ('EPA) on induction of Epstein-Barr virus antigens and cell differentiation
75. Sodium butyrate-inducible replication of human cytomegalovirus in a human epithelial cell line
76. Induction by sodium butyrate of cytomegalovirus replication in human endothelial cells
77. Relation of eukaryotic DNA replication to committed gene expression: General theory for gene control
78. Effects of n-butyrate on Epstein-Barr virus-carrying lymphoma lines
79. Combined effect of the extracts from Croton tiglium, Euphorbia lathyris or Euphorbia tirucalli and n-butyrate on Epstein-Barr virus expression in human lymphoblastoid P3HR-1 and Raji cells
80. Epstein-Barr virus-induced early polypeptides in Raji and NC37 cells activated by diterpene ester TPA in combination with N-butyrate
81. Effect of n-butyrate on cellular and viral DNA synthesis in cells latently infected with Epstein-Barr virus
82. Epstein-Barr virus-related DNA-binding proteins induced by n- butyrate in P3HR-1 cells
83. Immunochemical characterization of Epstein-Barr virus-associated early and late antigens in n-butyrate-treated P3HR-1 cells
84. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr virus (EBV)-associated lymphoma
85. Epstein-Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: Pharmacological re-activation of viral target genes with arginine butyrate
86. Butyrate-induced reactivation of the fetal globin genes: A molecular treatment for the beta-hemoglobinopathies
87. A short-term trial of butyrate to stimulate fetal-globin gene expression in the beta-globin disorders
88. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease
89. Effects of arginine butyrate on growth and chemosensitivity of human epithelial neoplasms
90. Phase I clinical trial of arginine butyrate in patients with refractory neoplasms
91. Phase I/II trial of arginine butyrate to induce viral TK gene expression in Epstein-Barr Virus (EBV)-associated lymphomas
92. Mutational analysis of sodium butyrate inducible elements in the human immunodeficiency virus type I long terminal repeat
93. Memory of butyrate induction by the Moloney murine sarcoma virus enhancer-promoter element
94. Sodium butyrate selectively induces tram scription of promoters adjacent to the MoMSV viral enhancer
95. Suppression of histone deacetylation in vivo and in vitro by sodium butyrate
96. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells
97. Cellular and viral DNA hypomethylation associated with induction of Epstein-Barr virus lytic cycle
98. Butyric acid: A small fatty acid with diverse biologic functions
99. Scaffold-attached region (SAR) Elements mediate transcriptional effects due to butyrate
100. Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease: Application of PCR-based analysis
101. DNA methylation and the Epstein-Barr virus